Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis
Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: Aminoglycosides are commonly used in the treatment of multidrug-resistant tuberculosis (MDR-TB). Their use can cause ototoxicity with irreversible hearing loss. The aim of this study was to determine the incidence and to identify factors associated to kanamycin-induced ototoxicity during MDR-TB treatment in Yaounde.
METHODS: The records of patients hospitalized in the pulmonology department of the Jamot Hospital of Yaounde between May 2008 and July 2015 (7 years) for treatment of MDR-TB with regimens containing kanamycin were analyzed. Logistic regression was used to identify for factors associated with ototoxicity during this treatment.
RESULTS: Of the 79 patients included, 60.7% were male and their median age (25th-75th percentile) was 31 (25-43) years. Eighteen (22.8%) patients had HIV infection. During treatment, the incidence of kanamycin-induced ototoxicity [95% confidence interval (95% CI)] was 36.7 (26.9-47.7) %. Factors independently associated with this ototoxicity [odds ratio (95% CI)] during MDR-TB treatment were age>40 years [13.47 (3.66-49.49)] and a body mass index<18.5kg/m2 [4.58 (1.36-15.44)].
CONCLUSION: The incidence of kanamycin-induced ototoxicity during MDR-TB treatment is relatively high. Taking these factors into consideration at the initiation of MDR-TB treatment would allow to reduce the occurrence of irreversible functional impairment induced by the treatment of MDR-TB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 37(2020), 5 vom: 01. Mai, Seite 369-375 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Ototoxicité liée à la kanamycine au cours du traitement de la tuberculose multirésistante |
|---|
| Beteiligte Personen: |
Poka-Mayap, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
59-01-8 |
|---|
| Anmerkungen: |
Date Completed 30.10.2020 Date Revised 30.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2019.12.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308636015 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308636015 | ||
| 003 | DE-627 | ||
| 005 | 20231225132142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2019.12.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308636015 | ||
| 035 | |a (NLM)32278508 | ||
| 035 | |a (PII)S0761-8425(20)30031-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Poka-Mayap, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis |
| 246 | 3 | 3 | |a Ototoxicité liée à la kanamycine au cours du traitement de la tuberculose multirésistante |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2020 | ||
| 500 | |a Date Revised 30.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: Aminoglycosides are commonly used in the treatment of multidrug-resistant tuberculosis (MDR-TB). Their use can cause ototoxicity with irreversible hearing loss. The aim of this study was to determine the incidence and to identify factors associated to kanamycin-induced ototoxicity during MDR-TB treatment in Yaounde | ||
| 520 | |a METHODS: The records of patients hospitalized in the pulmonology department of the Jamot Hospital of Yaounde between May 2008 and July 2015 (7 years) for treatment of MDR-TB with regimens containing kanamycin were analyzed. Logistic regression was used to identify for factors associated with ototoxicity during this treatment | ||
| 520 | |a RESULTS: Of the 79 patients included, 60.7% were male and their median age (25th-75th percentile) was 31 (25-43) years. Eighteen (22.8%) patients had HIV infection. During treatment, the incidence of kanamycin-induced ototoxicity [95% confidence interval (95% CI)] was 36.7 (26.9-47.7) %. Factors independently associated with this ototoxicity [odds ratio (95% CI)] during MDR-TB treatment were age>40 years [13.47 (3.66-49.49)] and a body mass index<18.5kg/m2 [4.58 (1.36-15.44)] | ||
| 520 | |a CONCLUSION: The incidence of kanamycin-induced ototoxicity during MDR-TB treatment is relatively high. Taking these factors into consideration at the initiation of MDR-TB treatment would allow to reduce the occurrence of irreversible functional impairment induced by the treatment of MDR-TB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aminoglycosides | |
| 650 | 4 | |a Aminosides | |
| 650 | 4 | |a Cameroon | |
| 650 | 4 | |a Cameroun | |
| 650 | 4 | |a Kanamycin | |
| 650 | 4 | |a Kanamycine | |
| 650 | 4 | |a Multidrug-resistant tuberculosis | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Ototoxicité | |
| 650 | 4 | |a Tuberculose multirésistante | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Kanamycin |2 NLM | |
| 650 | 7 | |a 59-01-8 |2 NLM | |
| 700 | 1 | |a Balkissou Adamou, D |e verfasserin |4 aut | |
| 700 | 1 | |a Pefura-Yone, E W |e verfasserin |4 aut | |
| 700 | 1 | |a Kuaban, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 37(2020), 5 vom: 01. Mai, Seite 369-375 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:5 |g day:01 |g month:05 |g pages:369-375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2019.12.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 5 |b 01 |c 05 |h 369-375 | ||